Updated on 2 June 2016
US-based medical device OEM manufacturer of orthopaedic and spine devices Tyber Medical has announced the acceptance of its entire interbody family of products into the Australian Registry of Therapeutic Goods.
"We are very excited to be in a position to meet the strong demand for our innovative products and provide access to our unique private label model in Australia. We expect that access to the Australian market will increase our growth trajectory and allow our private label partners a rapid pathway into the Australian market and vice versa for our Australian partners desiring entry into the US and European markets," said Tyber Medical CEO, Jeff Tyber.
Tyber further said, "Since the inception of Tyber Medical, requests for our products in Australia have been very strong. The commitment to a new market and length of the approval process discourages some, but in Australia, unlike many other markets, TGA approval, along with product reimbursement codes, ensures straightforward access. Tyber Medical's private label partners plan to begin launching products for this market in Q3 of 2016."
Tyber Medical says that its market analysis shows a large and increasing opportunity for their private label model and has strategic plans for the Australian market.